Hit and lead criteria in drug discovery for infectious diseases of the developing world
Hit and lead criteria in drug discovery for infectious diseases of the developing world
复制标题
DOI：
10.1038/nrd4683
复制
发表时间：
2015-11-01
影响因子：
120.1
通讯作者：
Slingsby, B. T.
中科院分区：
文献类型：
--
作者：
Katsuno, Kei;Burrows, Jeremy N.;Slingsby, B. T.
减轻影响发展中国家人民的传染病负担需要持续的合作药物发现努力。此类项目的化学起点的质量是提高临床成功可能性的关键因素，因此为命中和先导化合物的进展设定明确的进行/不进行标准非常重要。考虑到这一点，日本全球卫生创新技术基金召集了来自疟疾新药研发公司、被忽视疾病药物倡议和结核病联盟的专家以及比尔及梅林达·盖茨基金会的代表，为疟疾、结核病、内脏利什曼原虫和恰加斯病的命中和线索制定疾病特异性标准。在这里，我们提出了商定的标准，并讨论了基本原理。
Reducing the burden of infectious diseases that affect people in the developing world requires sustained collaborative drug discovery efforts. The quality of the chemical starting points for such projects is a key factor in improving the likelihood of clinical success, and so it is important to set clear go/no-go criteria for the progression of hit and lead compounds. With this in mind, the Japanese Global Health Innovative Technology (GHIT) Fund convened with experts from the Medicines for Malaria Venture, the Drugs for Neglected Diseases initiative and the TB Alliance, together with representatives from the Bill & Melinda Gates Foundation, to set disease-specific criteria for hits and leads for malaria, tuberculosis, visceral leishnnaniasis and Chagas disease. Here, we present the agreed criteria and discuss the underlying rationale.